Latest Breaking News On - Nct04055493 - Page 1 : comparemela.com

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

San antonioUnited statesWest germanOleg gluzGerman study groupAntonio breast cancerWest german study groupAdaptcycle trialThe addition of ovarian function suppression to endocrine therapyPatients with hormone receptor positiveEr2 negative early breast cancer